Latest news with #DepartmentofNeurosurgery
NDTV
4 days ago
- Health
- NDTV
Fluent In English, She Abruptly Stopped Speaking The Language. Here's Why
A Chinese woman, who was fluent in English, inexplicably lost her ability to speak the language after a cerebral haemorrhage. The 24-year-old's inability to speak the language after experiencing a strange medical ailment left the Chinese doctors handling the case perplexed and in disbelief. Wan Feng, the director of the neurosurgery department at Guangdong Provincial People's Hospital in Guangzhou, China, said the young lady suddenly experienced a very rare symptom after falling sick in class, Oddity Central reported. Following the incident, she could no longer speak English despite being once fluent in it. She could only speak Mandarin and Cantonese. For some reason, the young woman could still read and write it flawlessly. She was eventually hospitalised at Guangdong Provincial People's Hospital's Department of Neurosurgery to seek medical attention. Doctors initially thought her brain's ability to speak might have been impacted by a brain tumour. An MRI revealed she experienced a cerebral haemorrhage in the left motor part of her brain, which was in charge of communication, particularly affecting her ability to speak English. The woman reportedly underwent brain surgery to release the pressure in her brain. Soon after, she regained her English-speaking ability, the report added. In what was a completely opposite case 10 years ago, an elderly Chinese woman, who slipped into a coma for two weeks, woke up and spoke perfect English. But she couldn't speak a word of her native language, according to a report in the Business Standard. Liu Jieyu, 90, who worked as an English teacher but had not spoken the language for over 30 years, mysteriously acquired the ability to speak the language perfectly and forgot how to communicate in Chinese.
Hans India
23-05-2025
- Health
- Hans India
New gene therapy to target airway and lungs via nasal spray
US researchers have engineered a novel gene therapy to target the airway and lungs via a nasal spray. For gene therapy to work well, therapeutic molecules need to be efficiently delivered to the correct locations in the body. It is commonly done by using adeno-associated viruses (AAV) gene therapy. To improve the AAV's ability to deliver therapeutics specifically to the lungs and airway, researchers at the Mass General Brigham engineered a new version, called which can be administered with a nasal spray. In preclinical models, outperformed previous versions by more effectively targeting the airway and lungs and showing promise for respiratory and lung gene therapy, said the researchers in the paper published in the journal Cell Reports Medicine. "We noticed that which we initially engineered to enter the central nervous system, also efficiently targeted lung cells," said senior author FengFeng Bei, from the Department of Neurosurgery at Brigham and Women's Hospital. "This prompted us to further investigate for intranasal gene delivery to the respiratory airways," Bei added. In the study, outperformed previous versions (AAV6 and AAV9) in cell culture, mouse models, and non-human primate models. 'Our findings highlight as a promising vector for respiratory and lung gene therapy,' the team said. They then used the more efficient tool to deliver scar-preventing gene therapy for pulmonary fibrosis, using a mouse model of the respiratory disease. They also used the tool to deliver gene therapy for a viral infection, where the therapy prevented the replication of the SARS-CoV-2 virus in a mouse model of Covid-19. "Although further research is needed, our findings suggest that intranasal has strong translational potential as a promising delivery tool for targeting the airway and lung," said Bei.
Yahoo
14-05-2025
- Health
- Yahoo
GT Medical Technologies Welcomes New GammaTile® Center of Excellence Program Designation
Recognizing exceptional leadership in patient education and clinical skill in the GammaTile procedure TEMPE, Ariz., May 14, 2025 /PRNewswire/ -- GT Medical Technologies, a medical device company focused on improving the lives of patients with brain tumors, today announced Jersey Shore University Medical Center as the latest GammaTile® Center of Excellence Program designation. The program recognizes leaders in patient care dedicated to advancing brain tumor treatment. Physicians and their institutions who receive this designation have demonstrated an exceptional level of expertise in the GammaTile procedure by meeting specific clinical criteria, annual case minimums, and ongoing education requirements. The following physicians are now recognized with achievement: Shabbar F. Danish, MD, FAANS, Professor and Chair, Department of Neurosurgery Nitesh V. Patel, MD, FAANS, Assistant Professor, Department of Neurosurgery, Co-Director of Neurosurgical Oncology Timothy H. Chen, MD, Medical Director, CNS, Department of Radiation Oncology "This designation is a powerful acknowledgment of our commitment to advancing brain tumor care. Innovative treatments like GammaTile are changing what's possible for patients and their families—and we're honored to be part of that progress," Shabbar F. Danish, MD, Chair, Neurosurgery at Jersey Shore University Medical Center. GammaTile is an innovative form of radiation therapy placed at the time of tumor removal surgery, delivering immediate, targeted radiation to the tumor site when cancer cells are most vulnerable. Unlike conventional approaches, which often require a delay between surgery and radiation therapy to allow for wound healing, GammaTile eliminates this treatment gap. By delivering immediate, localized radiation directly at the tumor site, it is designed to maximize the treatment's effectiveness against remaining cancer cells and reduce the risk of regrowth.1 About GT Medical Technologies, Medical Technologies was founded by a dedicated team of brain tumor specialists to address unmet needs in brain tumor treatment. The company is committed to improving the lives of patients with brain tumors through innovative solutions that elevate the standard of care. About GammaTileGammaTile is an FDA-cleared, bioabsorbable collagen implant embedded with radiation seeds, designed for patients with operable brain tumors. By delivering radiation directly from within—placed into the surgical cavity at the time of tumor removal—GammaTile provides immediate, localized treatment. This approach targets remaining cancer cells when they are most vulnerable to help prevent regrowth, while minimizing radiation exposure to healthy brain tissue. Since its full market launch in the United States in March 2020, GammaTile has been adopted by more than 100 leading centers, underscoring its growing acceptance in both academic and community healthcare settings. For more information, visit and follow @GammaTile on Facebook, Instagram, LinkedIn and X. Media ContactDawn FallonNew Dawn Communications LLCDfallon@ References Garcia MA et al. J Neurooncol. 166:203-212 (2024). View original content to download multimedia: SOURCE GT Medical Technologies Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
India Gazette
14-05-2025
- Health
- India Gazette
MRgFUS technology eliminates Parkinson's tremors with non-Invasive procedure
New Delhi [India], May 14 (ANI): A retired school teacher, had been silently suffering from debilitating hand tremors for several years--tremors that stripped her of her independence and confidence. Once a vibrant woman who loved socialising, she became withdrawn, embarrassed by her inability to perform simple tasks such as drinking water, eating a sandwich, or writing her name. Despite consulting multiple specialists and trying various medications, nothing brought relief. The suggestion of undergoing Deep Brain Stimulation--an invasive surgical procedure involving the implantation of a brain pacemaker--left her distressed and fearful. She continued to live with her condition until she discovered a groundbreaking, non-surgical alternative: MRgFUS (MRI-Guided Focused Ultrasound) Thalamotomy. According to Dr. Anshu Rohatgi, Vice Chairman, Department of Neurology at Sir Gangaram Hospital, 'The patient underwent MRgFUS Thalamotomy at SGRH and experienced immediate results. Her right hand became tremor-free during the procedure itself. The next morning, she joyfully drank water without spilling, ate a sandwich on her own, and wrote her name with a steady hand--big victories that marked a huge leap in reclaiming her life.' MRgFUS is a state-of-the-art, non-invasive procedure that uses highly focused ultrasound beams guided by MRI to target and treat specific brain areas responsible for tremors. It is particularly effective in patients with Essential Tremors and Tremor-Dominant Parkinson's Disease. Dr. Ajay Swaroop, Chairman, Board of Management, Sir Ganga Ram hospital said, 'SGRH has a tradition of providing cutting edge technology for patients. In this series we bring, for the first time in north India, a non-invasive treatment for debilitating movement disorders. This treatment will be a boon for patients with no relief from conservative medical treatment. This is our contribution to constantly be the first in patient care.' Dr Satnam Chhabra, Chairman, Department of Neurosurgery said, 'This highly precise procedure was performed by a team comprising of neurologists, neurosurgeons, and neuroradiologists. As this is completely non-invasive, all risks associated with open surgery are effectively avoided.' (ANI)
Hans India
04-05-2025
- Health
- Hans India
Ashok Mahapatra calls on SOA president
Bhubaneswar: Padma Shri awardee and eminent neurosurgeon Ashok Kumar Mahapatra called on Siksha 'O' Anusandhan (SOA) Founder President Manojranjan Nayakon Saturday. The meeting took place after Mahapatra received Padma Shri for his outstanding contribution in the field of medical science. He received the award on April 28 from President Droupadi Murmu at a special ceremony held atRashtrapati Bhavan in New Delhi. A distinguished neurosurgeon of international repute, Mahapatra hasserved as the ViceChancellor of SOA and currently holds the position of ChiefAdvisor (Health Sciences) in the he held the position of Head of the Department of Neurosurgery atAIIMS, New Delhi, and was also the first Director of AIIMS, Bhubaneswar. His exemplarywork has earned him a place among the top five neurosurgeons globally. During the meeting, Mahapatra discussed various aspects of SOA'sgrowth, development strategies and academic congratulated Mahapatra on being conferred the Padma Shri.
